课题基金 / 基金详情

Molecular mechanisms of drug resistance in cancer.-GIST resistant to imatinib as a model-

Molecular mechanisms of drug resistance in cancer.-GIST resistant to imatinib as a model-
癌症耐药的分子机制。-GIST对伊马替尼耐药的模型-
批准号:
16390363
负责人:
NISHIDA Toshirou
金额:
$8.96万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2004
资助国家:
日本
项目状态:
已结题
起止时间:
2004 至 2006

项目摘要

项目成果

NISHIDA Toshirou的其他基金

相似基金

相关文献

中文摘要
翻译
对抗癌药物的耐药性是影响晚期肿瘤患者预后和生活质量的重要因素。耐药机制有多种,但对新出现的靶点药物耐药的分子机制尚未阐明。本项目以GIST对伊马替尼和舒尼替尼耐药为模型,研究了靶向药物的分子机制。尽管伊马替尼对晚期GIST有较高的疗效,并能改善GIST患者的预后,但半数患者在治疗2年后出现了对伊马替尼耐药的GIST。我们重点分析了KIT和PDGFRA基因的分子机制,并分析了42例伊马替尼耐药GIST患者中的25例(48个耐药灶),其中5例为原发性耐药,37例为继发性耐药(1)。顽固性GIST的临床特征:CT显示肿块增大15例,肿块样结节10例,新发3例。部分患者表现为混合型。手术的安全性和治疗效果:22例局灶性耐药或症状性全身耐药的患者接受了手术和/或RFA。手术治疗顽固性病变通常是安全且可接受的,只有三种轻微并发症。尽管与未手术的患者相比,全身性抵抗的手术结果令人失望,但没有延长预后,局灶性进展的手术可延长6个月的PFS。完全切除耐药病灶的患者预后好得多。KIT和PDGFRA蛋白的表达和下游激酶的激活:所有耐药病变在免疫组织化学中均显示表达KIT蛋白的活梭形和/或上皮样肿瘤细胞。下游激酶包括AKT和MAPK也被重新激活(4)。KIT和/或PDGFRA基因的获得性突变:20例患者在KIT基因的激酶结构域具有获得性突变(除原发性突变外,Ex13 11例,Ex14 1例,Ex17 10例,Ex16+17 1例)。这些突变在相同的等位基因中,抗性病变表现为克隆发育。其他5例患者仅有原发突变。突变和舒尼替尼耐药性:6例伊马替尼耐药GIST患者接受舒尼替尼作为二线治疗。5例患者对舒尼替尼出现原发性耐药,包括3例Ex 11+ Ex 17突变、Ex 9 +无附加突变和Ex 11+ Ex 13突变。最后一组患者由于延长肠切除术,血液中舒尼替尼水平没有升高。一名Ex 11+Ex 13突变的患者对舒尼替尼表现出PR,然而,Ex 17的第三个突变允许舒尼替尼下的另一种发展。因此,KIT基因ex17的第二或第三个突变赋予了对舒尼替尼的抗性。综上所述,KIT基因附加突变的靶耐药可能是对伊马替尼和舒尼替尼分子靶药继发耐药的主要原因。少
英文摘要
Resistance to the anticancer drugs is a determinant of the prognosis and QOL of patients with advanced cancer. There have been several mechanisms for drug resistance, however, molecular mechanisms of resistance to newly emerged target agents have not yet been elucidated. In this project, we have investigated molecular mechanisms of target agents using GIST resistant to imatinib and sunitinib as a model. Although imatinib has shown high activities on advanced GIST and improves the prognosis of GIST patients, half of patients suffered from appearance of imatinib-resistant GIST after 2 years treatment. We have focused analysis of a molecular mechanism on the KIT and PDGFRA genes and analyzed 25 patients (48 resistant lesions) of 42 patients who have imatinib-resistant GIST including 5 primary resistance and 37 secondary.(1). Clinical features of resistant GIST :CT revealed that 15 lesions showed a mass enlargement, 10 a nodule in a mass appearance, and only three lesions appeared as a new … More lesion. Some patients showed mixed type.(2). Safety and therapeutic effects of surgery :Twenty two patients with focal resistance or symptomatic systemic resistance underwent surgery and/or RFA. Surgery for resistant lesions is generally safe and acceptable with three minor complications. Although surgery for systemic resistance showed disappointed results without no prolongation of the prognosis compared to patients without surgery, surgery for focal progression conferred additional 6 months PFS. Patients with complete resection of resistant lesions had much better prognosis.(3). Expression of KIT & PDGFRA proteins and activations of downstream kinases :All resistant lesions show viable spindle and/or epithelioid tumor cells which express KIT proteins in immunohistochemistory. Downstream kinases including AKT and MAPK are also re-activated.(4). Acquired mutations in the KIT and/or PDGFRA genes :twenty patients are endowed with acquired mutations in kinase domains of the KIT gene (11 in Ex13, 1 in Ex14, 10 in Ex17, 1 in Ex16+17 in addition to primary mutations). These mutations are in the same allele and resistant lesions showed clonal development. The other 5 patients had only primary mutations.(5). Mutations and sunitinib resistance :Six patients with imatinib-resistant GIST received sunitinib as a second-line therapy. Five patients showed primary resistance to sunitinib including three Ex 11+ Ex 17 mutations, Ex 9 +no additional mutation, and Ex 11+ Ex 13 mutation. The last patients had no increase in blood levels of sunitinib because of extended bowel resection. One patient with Ex 11+Ex 13 mutation showed PR to sunitinib, however, third mutation in Ex 17 allowed another development under sunitinib. Thus, second or third mutation in Ex 17 of the KIT gene conferred resistance to sunitinib.In summary, target resistance with additional mutations in the KIT gene may be a main cause of secondary resistance to molecular targets agent of imatinib and sunitinib. Less
期刊论文(18)
专著(0)
科研奖励(0)
会议论文
GISTの診断と治療 実践マニュアル
GIST诊断与治疗实用手册
DOI: --
发表时间: 2006
期刊:
影响因子: --
作者: [Akasaka Y, Ishii T et al., 櫻井信司 共著]
通讯作者: 櫻井信司 共著
GISTの診断と治療 実践マニュアル(西田俊朗編)
GIST诊治实用手册(西田敏郎主编)
DOI: --
发表时间: 2006
期刊:
影响因子: --
作者: [Uchikoshi F, et al., 西田俊朗 他]
通讯作者: 西田俊朗 他
Angiogenesis, which is essential for cancer growth, is a diagnostic and therapeutic target.
血管生成对于癌症生长至关重要,是诊断和治疗的目标。
DOI: --
发表时间: 2005
期刊: J Gastroenterology 40
影响因子: --
作者: [Nishitani A, et al., Nishida T.]
通讯作者: Nishida T.
DOI: 10.1007/s00464-005-0252-0
发表时间: 2006-04-01
期刊: SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
影响因子: 3.1
作者: [Yasumasa, K, Nakajima, K, Nishida, T]
通讯作者: Nishida, T
共 14 条
    Mechanisms of immune responses by toll-like receptor against Infection and organ failure
    • 批准号:
      13671232
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.3万
    • 财政年份:
      2001
    • 负责人:
      NISHIDA Toshirou
    • 依托单位:
    Mechanisms of the gastrointestinal motility dysfunction under septic conditions - a role of Interstitial Cells of Cajal -
    • 批准号:
      11557093
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $8.13万
    • 财政年份:
      1999
    • 负责人:
      NISHIDA Toshirou
    • 依托单位:
    Mechanisms of sepsis-induced cholestatic liver injury
    • 批准号:
      11671162
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.3万
    • 财政年份:
      1999
    • 负责人:
      NISHIDA Toshirou
    • 依托单位:
    Role of the c-kit tyrosine kinase in the genesis of gastrointestinal stromal tumors.
    • 批准号:
      09671305
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.3万
    • 财政年份:
      1997
    • 负责人:
      NISHIDA Toshirou
    • 依托单位:
    海外基金